TrialStudy to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
Trial details
- Registry ID
- NCT04262856
- Phase
- Phase 2
Drug research
Zimberelimab
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as AB122
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerNCT04262856 | RCUS | Phase 2 | Completed | 2025-07-09Actual |
| Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173 | RCUS | Phase 2 | Active not recruiting | 2027-05Estimated |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyNCT05568095 | RCUS | Phase 3 | Completed | 2026-08-28Actual |
| A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesNCT05329766 | RCUS | Phase 2 | Active not recruiting | 2027-01Estimated |
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Trial details
- Registry ID
- NCT04736173
- Phase
- Phase 2
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
Trial details
- Registry ID
- NCT05568095
- Phase
- Phase 3
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Trial details
- Registry ID
- NCT05329766
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |